Fallopian tube cancer+1
RecruitingStudy of mirvetuximab soravtansine dosing schedules for patients with platinum-resistant advanced ovarian, peritoneal, or fallopian tube cancer with high folate receptor expression
Study of mirvetuximab soravtansine dosing schedules for patients with platinum-resistant advanced ovarian, peritoneal, or fallopian tube cancer with high folate receptor expression
- Disease:Fallopian tube cancerOvarian epithelial cancer
- Substances:Prednisolone AcetateMirvetuximab Soravtansine
Spain- Participants:18–64 years
- Substances:Prednisolone Acetate
- Sponsor:AbbVie Deutschland GmbH & Co. KG












